HC Wainwright & Co. Reiterates Buy on United Therapeutics, Maintains $400 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on United Therapeutics (NASDAQ:UTHR) and maintained a $400 price target.
August 01, 2024 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on United Therapeutics and maintained a $400 price target.
The reiteration of a Buy rating and a high price target of $400 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100